The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

CNW/ - Although significant progress has been made in the past several decades in reducing smoking rates in Canada , the Council of Chief Medical ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

ROCHESTER, Minn. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Cerebras Systems, in collaboration with Mayo Clinic, announced significant progress in developing artificial intelligence tools to advance ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target. Eli Lilly on ...

Today, a brief rundown of news involving Pfizer, AbbVie and Royalty Pharma, as well as updates from Biogen and Alkeus Pharmaceuticals that you may have missed. Barinthus Biotherapeutics on Friday said ...